MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • News
  • Store
  • Brokers
  • Download
  • Economic Calendar
  • Trading Signals
  • WebTerminal
  • Heatmap
  • Русский
  • 中文
  • Español
  • Português
  • 日本語
  • Deutsch
  • 한국어
  • Français
  • Italiano
  • Türkçe
Altimmune, Inc. Common Stock

ALT

#3036
Altimmune, Inc. Common Stock
3.27 USD
+1.24%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
3.25
3.29
Year Range
2.87
7.73
Daily Change
+1.24%
Monthly Change
-9.17%
6 month change
-17.84%
Year Change
-28.60%
Previous Close
3.23
Open
3.29
Bid
Ask
Low
3.25
High
3.29
Volume
170
  1. Markets
  2. US Stock Market
  3. Healthcare
  4. ALT
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 425.33 M
  • Employee 57
  • Founded 1997
  • CEO Jerry Durso
  • Website www.altimmune.com
  • Headquarter Delaware, United States
  • FIGI BBG000FXML90
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
425.33 M Market capitalization
Price to earnings ratio
-3.61
Price to sales ratio
7 757.46

News

Zacks Zacks
NVO LLY ALT MDGL
2026.03.26
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
Zacks Zacks
NVO LLY ALT
2026.03.26
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts
Zacks Zacks
NVO LLY ALT MDGL
2026.03.26
ALT Pemvidutide Explained: What Makes It Different in MASH
Investing Investing
ALT
2026.03.17
H.C. Wainwright raises Altimmune stock price target on MASH focus
Investing Investing
ALT
2026.03.12
Altimmune at Barclays Conference: Advancing Pemvidutide’s Potential
Investing Investing
ALT
2026.03.11
Altimmune at Leerink Conference: Strategic Advances in MASH Treatment
Investing Investing
ALT
2026.03.09
Altimmune CEO Durso buys $70,790 in shares
Investing Investing
ALT
2026.03.09
Altimmune CFO Weaver buys $17,700 in shares
Seeking Alpha Seeking Alpha
ALT
2026.03.05
Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Investing Investing
LLY MDGL ALT NVO
2026.03.05
William Blair reiterates Altimmune stock rating on trial data
Investing Investing
ALT
2026.03.05
Altimmune earnings missed by $0.02, revenue fell short of estimates
Investing Investing
ALT
2026.03.05
Altimmune stock edges down on fourth quarter earnings miss

Markets

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Charts & Ideas

  • Trading Ideas
  • Education Ideas
  • Charts

MQL5 Community

  • Market
  • Signals
  • Forum
  • Articles
  • CodeBase

News

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Brokers

  • All Brokers
  • Forex
  • Stock
  • Metals
MetaTrader 5
Scan to install from App Store
Scan to install from Google Play
Scan to install from Huawei AppGallery
Scan to install APK
MQL5 Channels
Scan to install from App Store
Scan to install from Google Play
Scan to install from Huawei AppGallery
Scan to install APK
Economic Calendar
Scan to install from App Store
Scan to install from Google Play
Scan to install from Huawei AppGallery
Scan to install APK
Risk Disclosure Terms of Use Help Contacts and Requests Legal
Copyright 2000-2026, MetaQuotes Ltd